Dashboard
1
The company has declared negative results in Mar'2025 after 6 consecutive positive quarters
- INTEREST(HY) At CNY 0.06 MM has Grown at 802.61%
- OPERATING PROFIT MARGIN(Q) Lowest at 39.74 %
2
With ROE of 12.05%, it has a attractive valuation with a 1.22 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,966 Million (Small Cap)
10.00
NA
0.60%
-0.75
12.05%
1.22
Revenue and Profits:
Net Sales:
172 Million
(Quarterly Results - Jun 2025)
Net Profit:
70 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.65%
0%
-22.65%
6 Months
-9.36%
0%
-9.36%
1 Year
-9.83%
0%
-9.83%
2 Years
-32.53%
0%
-32.53%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Hangzhou AGS MedTech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Hangzhou AGS MedTech Hits Day Low at CNY 68.17 Amid Price Pressure
Hangzhou AGS MedTech Co., Ltd. faced a significant decline in stock value on October 13, 2025, reaching an intraday low. Over the past week and month, the company's stock has decreased, contrasting with the performance of the China Shanghai Composite. However, it has shown resilience over the past year.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
38.60%
EBIT Growth (5y)
56.97%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
36.93
Tax Ratio
14.89%
Dividend Payout Ratio
37.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
67.58%
ROE (avg)
11.26%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.22
EV to EBIT
3.91
EV to EBITDA
3.75
EV to Capital Employed
1.90
EV to Sales
1.71
PEG Ratio
NA
Dividend Yield
0.60%
ROCE (Latest)
48.48%
ROE (Latest)
12.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
172.00
150.80
14.06%
Operating Profit (PBDIT) excl Other Income
68.30
68.20
0.15%
Interest
0.00
0.00
Exceptional Items
1.00
0.00
Consolidate Net Profit
69.80
71.70
-2.65%
Operating Profit Margin (Excl OI)
376.40%
436.20%
-5.98%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 14.06% vs 31.82% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -2.65% vs 60.76% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
628.40
504.40
24.58%
Operating Profit (PBDIT) excl Other Income
292.30
223.40
30.84%
Interest
0.40
0.30
33.33%
Exceptional Items
2.10
0.40
425.00%
Consolidate Net Profit
293.40
217.20
35.08%
Operating Profit Margin (Excl OI)
449.20%
427.60%
2.16%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 24.58% vs 37.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 35.08% vs 49.79% in Dec 2023
About Hangzhou AGS MedTech Co., Ltd. 
Hangzhou AGS MedTech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






